Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Relay Therapeutics, Inc. Common Stock

RLAY

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

Last trade $16.74
Day change -$0.53 (-3.07%)
Day range $16.54 – $17.54
Volume 1,528,581
Market cap $3.82B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.82B
Price / earnings
—
Price / book
4.66×
Price / sales
368.69×
EV / sales
356.69×
EV / EBITDA
-11.59×

Profitability

Earnings per share
-$1.33
Return on assets
-32.58%
Return on equity
-35.87%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
14.62×
Quick ratio
14.62×
Cash ratio
2.1×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$214.02M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RLAY, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$350K$3M$7M$0$677K$7.68M$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$350K$3M$7M$0$677K$7.68M$0
Selling, general and administrative$13.11M$14.69M$11.03M$12.22M$12.13M$13.63M$18.74M$16.9M
Research and development$77.14M$76.48M$70.56M$55.42M$68.26M$63.9M$73.81M$68.08M
Total operating expenses$90.25M$91.17M$81.59M$67.63M$80.39M$77.52M$92.55M$84.98M
Operating income-$90.25M-$90.82M-$78.59M-$60.63M-$80.39M-$76.85M-$84.87M-$84.98M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$81.75M-$83.71M-$73.29M-$54.89M-$74.15M-$70.38M-$77.07M-$76M
Income taxes$0$0$0$0$0$0$0$0
Net income-$81.75M-$83.71M-$73.29M-$54.89M-$74.15M-$70.38M-$77.07M-$76M
Net income attributable to common shareholders-$81.75M-$83.71M-$73.46M-$54.89M-$74.15M-$70.38M-$76.04M-$76M
EBITDA-$89.97M-$90.46M-$78.09M-$60.03M-$79.64M-$75.85M-$83.66M-$83.65M
Basic earnings per share-$0.37-$0.41-$0.41-$0.32-$0.43-$0.41-$0.46-$0.45
Diluted earnings per share-$0.37-$0.41-$0.41-$0.32-$0.43-$0.41-$0.46-$0.45

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option

Elevar Therapeutics announced FDA approval of Lyrfigtu (lirafugratinib) for treating cholangiocarcinoma patients with FGFR2 fusion or rearrangement. The drug demonstrated a 46% objective response rate and 11.8-month median duration of response in the Phase 1/2 ReFocus trial. Lyrfigtu is expected to be available in the U.S. by Q4 2026 and represents a second-line treatment option for this rare bile duct cancer.

GlobeNewswire Inc.

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

Relay Therapeutics announced that management will participate in fireside chats at the Wells Fargo Healthcare Conference on September 8, 2026 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. The clinical-stage precision medicine company is developing therapies for cancer and genetic diseases, with its lead asset zovegalisib currently in Phase 3 trials for HR+/HER2- metastatic breast cancer.

The Motley Fool

Is Relay Therapeutics a Buy After Promising Trial Results?

Relay Therapeutics announced promising phase 2 trial results for zovegalisib in treating vascular anomalies, with a 60% volumetric response rate. The clinical-stage biotech has a well-capitalized position with $642 million in cash, a structured path to market including a planned phase 3 trial in early 2027, and a diversified pipeline. However, as a pre-revenue company, it faces significant binary risk dependent on the clinical and regulatory success of its lead therapy.

GlobeNewswire Inc.

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Relay Therapeutics priced an underwritten public offering of 22.9 million shares at $12.00 per share, raising approximately $275 million in gross proceeds. The offering is expected to close on May 22, 2026. The clinical-stage biotech company is developing precision medicine therapies, with its lead asset zovegalisib currently in Phase 3 trials for HR+/HER2- metastatic breast cancer and being investigated for PIK3CA-driven vascular anomalies.

The Motley Fool

Why Relay Therapeutics Stock Popped on Wednesday

Relay Therapeutics stock surged 7.87% on Wednesday following positive Phase 2 results for zovegalisib, a vascular anomalies treatment, which showed 60% patient response rates at 12 weeks—exceeding analyst expectations. Two analysts raised their price targets (Barclays to $27, Citizens JMP to $21) and maintained buy ratings. The gains were partially offset by the company's announcement of a secondary stock offering exceeding $200 million.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.